Showing results (11-20 of 45) with videos related to

Sort By:
Pageof 5
Developmental Biology|October 31, 2006
lin-35/Rb and the CoREST ortholog spr-1 coordinately regulate vulval morphogenesis and gonad development in C. elegansAaron M Bender, Natalia V Kirienko, Sara K Olson, et al.
ACS Chemical Neuroscience|January 18, 2023
DARK Classics in Chemical Neuroscience: MethaqualoneJoseph A Inger, Elias R Mihan, Jhansi U Kolli, et al.
Journal of Medicinal Chemistry|August 16, 2023
2B Determined: The Future of the Serotonin Receptor 2B in Drug DiscoveryAaron M Bender, Lauren C Parr, William B Livingston, et al.
Bioorganic & Medicinal Chemistry Letters|December 25, 2013
Synthesis and evaluation of 4-substituted piperidines and piperazines as balanced affinity μ opioid receptor (MOR) agonist/δ opioid receptor (DOR) antagonist ligandsAaron M Bender, Mary J Clark, Michael P Agius, et al.
Plos Pathogens|January 10, 2020
The C. elegans CHP1 homolog, pbo-1, functions in innate immunity by regulating the pH of the intestinal lumenSaida Benomar, Patrick Lansdon, Aaron M Bender, et al.
ACS Medicinal Chemistry Letters|December 30, 2015
Rapid Synthesis of Boc-2',6'-dimethyl-l-tyrosine and Derivatives and Incorporation into Opioid PeptidomimeticsAaron M Bender, Nicholas W Griggs, Chao Gao, et al.
Assay and Drug Development Technologies|March 17, 2023
Identification of Potent, Selective, and Peripherally Restricted Serotonin Receptor 2B Antagonists from a High-Throughput ScreenAaron M Bender, Michael S Valentine, Joshua A Bauer, et al.
ACS Chemical Neuroscience|May 5, 2015
Asymmetric synthesis and in vitro and in vivo activity of tetrahydroquinolines featuring a diverse set of polar substitutions at the 6 position as mixed-efficacy μ opioid receptor/δ opioid receptor ligandsAaron M Bender, Nicholas W Griggs, Jessica P Anand, et al.
ACS Chemical Neuroscience|April 24, 2018
Structure-Activity Relationships of Pan-Gαq/11 Coupled Muscarinic Acetylcholine Receptor Positive Allosteric ModulatorsAlice E Berizzi, Aaron M Bender, Craig W Lindsley, et al.
Journal of Medicinal Chemistry|February 20, 2013
Opioid peptidomimetics: leads for the design of bioavailable mixed efficacy μ opioid receptor (MOR) agonist/δ opioid receptor (DOR) antagonist ligandsHenry I Mosberg, Larisa Yeomans, Aubrie A Harland, et al.
Pageof 5